SEB Equities analyst Thomas Bowers upgraded Zealand Pharma (ZLDPF) to Buy from Hold with a DKK 475 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma, Roche to advance petrelintide for weight management to Phase 3
- Zealand Pharma appoints Eric Rojas as VP, head of IR
- Zealand Pharma Advances Obesity Pipeline With Completed Petrelintide Dose Study
- Zealand Pharma establishes U.S. research hub in Cambridge, Massachusetts
- Zealand Pharma price target lowered to DKK 275 from DKK 450 at Deutsche Bank